NIH Director Page NIH Health Information Page NIH Impact NIH Fact Sheets NIH Social Media and Outreach
EurekAlert! - National Institutes of Health  
LINKS

Resources

 

NIH Main

 

NIH Research News

 

Funded News

 
  For News & Research
  NIH Videos
  eColumn: NIH Research Matters
  NIH News in Health
  NIH Fact Sheets
 
  Additional Resources
  NIH Home Page
 

About NIH

  NIH Health Information
  Pub Med
  MedlinePlus
  Clinical trials.gov
  More News and Events Sources
  NIH News and Events, Special Interest
 
  RSS Feed RSS Feed
  Back to EurekAlert!
 

 


Department of Health and Human Services

News from the National Institutes of Health

NIH Research News


Key: Meeting M      Journal J      Funder F

Showing releases 76-96 out of 96.

<< < 1 | 2 | 3 | 4

Public Release: 3-Mar-2015
Nature
Scientists map memorable tunes in the rat brain
Lights, sound, action: we are constantly learning how to incorporate outside sensations into our reactions in specific situations. In a new study, brain scientists have mapped changes in communication between nerve cells as rats learned to make specific decisions in response to particular sounds. The team then used this map to accurately predict the rats' reactions. These results add to our understanding of how the brain processes sensations and forms memories to inform behavior.
NIH/National Institute of Neurological Disorders and Stroke, NIH/National Institute of Deafness and Other Communications Disorders

Contact: Christopher G. Thomas
nindspressteam@ninds.nih.gov
NIH/National Institute of Neurological Disorders and Stroke

Public Release: 27-Feb-2015
Cell
HIV controls its activity independent of host cells
A major hurdle to curing people of HIV infection is the way the virus hides in a reservoir composed primarily of dormant immune cells. It is generally believed that HIV does not replicate in these cells because the virus depends on active cellular machinery to do so. Now, two new papers by NIAID grantees propose that the virus itself -- not cells -- controls whether HIV is replicating, and that periods of latency paradoxically give the virus a survival advantage.
NIH/National Institute of Allergy and Infectious Diseases

Contact: Laura S. Leifman
laura.sivitz@nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases

Public Release: 27-Feb-2015
Liberia-US clinical research partnership opens trial to test Ebola treatments
In partnership with the Liberian government, the National Institute of Allergy and Infectious Diseases today launched a clinical trial to obtain safety and efficacy data on the investigational drug ZMapp as a treatment for Ebola virus disease. The study, which will be conducted in Liberia and the United States, is a randomized controlled trial enrolling adults and children with known Ebola virus infection.
NIH/National Institute of Allergy and Infectious Diseases

Contact: Jennifer Routh
jennifer.routh@nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases

Public Release: 24-Feb-2015
Nature Communications
NIH-funded researchers identify genetic region associated with peanut allergy
An NIH-funded research suggests that changes in a small region of chromosome 6 are risk factors for peanut allergy in US children of European descent. The genetic risk area is located among two tightly linked genes that regulate the presentation of allergens and microbial products to the immune system. This study is the first to use a genome-wide screening approach in patients with well-defined food allergy to identify risks for peanut allergy.
NIH/National Institute of Allergy and Infectious Diseases

Contact: Linda Huynh
linda.huynh@nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases

Public Release: 23-Feb-2015
2015 AAAAI Annual Meeting
New England Journal of Medicine
Study finds peanut consumption in infancy prevents peanut allergy
Introduction of peanut products into the diets of infants at high risk of developing peanut allergy was safe and led to an 81 percent reduction in the subsequent development of the allergy, a clinical trial has found. The study was supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and was conducted by the NIAID-funded Immune Tolerance Network.
NIH/National Institute of Allergy and Infectious Diseases

Contact: Linda Huynh
niaidnews@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases

Public Release: 18-Feb-2015
NIH-sponsored HIV vaccine trial launches in South Africa
A clinical trial has launched in South Africa to study an investigational HIV vaccine regimen for safety and the immune responses it generates in volunteers. This experimental regimen is based on the one tested in the RV144 trial - -the first to demonstrate that a vaccine can protect people from HIV infection -- but is designed to potentially provide greater protection and is adapted to the predominant HIV subtype in southern Africa.
NIH/National Institute of Allergy and Infectious Diseases

Contact: Laura S. Leifman
laura.sivitz@nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases

Public Release: 18-Feb-2015
Nature
NIH-funded scientists create potential long-acting HIV therapeutic
Scientists have created a new molecule that shows promise for controlling HIV without daily anti-retroviral drugs. The molecule foils a wider range of HIV strains in the laboratory than any known broadly neutralizing HIV antibody and is more powerful than some of the most potent of these antibodies. In addition, the molecule safely protected monkeys from infection with an HIV-like virus during a 40-week study period.
NIH/National Institute of Allergy and Infectious Diseases

Contact: Laura S. Leifman
laura.sivitz@nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases

Public Release: 18-Feb-2015
NIH-supported trials to evaluate long-acting injectable anti-retrovirals to prevent HIV
Two new clinical trials are examining the safety and acceptability of antiretroviral medicines administered via injection as a means of protecting against HIV infection. The studies are being funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and conducted by the NIAID-funded HIV Prevention Trials Network (HPTN).
NIH/National Institute of Allergy and Infectious Diseases

Contact: Robin Tricoles
niaidnews@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases

Public Release: 18-Feb-2015
NIH expands key tuberculosis research program
The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, is expanding its Tuberculosis Research Units program in an effort to drive innovation in tuberculosis research. NIAID is awarding up to $15.2 million in fiscal year 2015 and as much as $105.3 million over seven years to fund four institutions that will act as a collaborative TBRU network.
NIH/National Institute of Allergy and Infectious Diseases

Contact: Emily Mullin
niaidnews@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases

Public Release: 18-Feb-2015
Nature
NIH-supported researchers map epigenome of more than 100 tissue and cell types
Much like mapping the human genome laid the foundations for understanding the genetic basis of human health, new maps of the human epigenome may further unravel the complex links between DNA and disease. The epigenome is part of the machinery that helps direct how genes are turned off and on in different types of cells.
NIH/National Institute of Environmental Health Sciences, NIH/National Institute on Drug Abuse

Contact: Robin Mackar
rmackar@niehs.nih.gov
919-541-0073
NIH/National Institute of Environmental Health Sciences

Public Release: 18-Feb-2015
New England Journal of Medicine
Eylea outperforms other drugs for diabetic macular edema with moderate vision loss
In an NIH-supported clinical trial comparing three drugs for diabetic macular edema, Eylea provided greater visual improvement, on average, than did Avastin or Lucentis when vision was 20/50 or worse at the start of the trial. However, the three drugs resulted in similar average improvement when starting vision was 20/40 to 20/32. Investigators found no major differences in the safety of the three drugs. The trial was funded by the National Eye Institute.
National Institutes of Health, NIh/National Eye Institute, NIH/National Institute of Diabetes and Digestive and Kidney Diseases

Contact: Dustin Hays
neinews@nei.nih.gov
301-496-5248
NIH/National Eye Institute

Public Release: 16-Feb-2015
Nature
NIH researchers reveal link between powerful gene regulatory elements and autoimmune diseases
Investigators with the National Institutes of Health have discovered the genomic switches of a blood cell key to regulating the human immune system. The findings, published in Nature today, open the door to new research and development in drugs and personalized medicine to help those with autoimmune disorders such as inflammatory bowel disease or rheumatoid arthritis.
National Institutes of Health, NIH/National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH/National Human Genome Research Institute, NIH/National Cancer Institute

Contact: Trish Reynolds
reynoldsp2@mail.nih.gov
301-496-8190
NIH/National Institute of Arthritis and Musculoskeletal and Skin Diseases

Public Release: 12-Feb-2015
Emerging Infectious Diseases
NIH Ebola study in macaques provides timeframes for post-mortem viral stability
To determine how long Ebola virus could remain infectious in a body after death, NIH scientists sampled deceased Ebola-infected monkeys and discovered the virus remained viable for at least seven days. They also detected non-infectious viral RNA for up to 70 days post-mortem.
NIH/National Institute of Allergy and Infectious Diseases

Contact: Ken Pekoc
kpekoc@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases

Public Release: 11-Feb-2015
Nationwide study reports shifts in Americans' use of natural products
A nationally representative survey shows that natural product use in the United States has shifted since 2007, with some products becoming more popular and some falling out of favor. Overall, natural products (dietary supplements other than vitamins and minerals) remain the most common complementary health approach. The complementary health questionnaire was developed by NIH's National Center for Complementary and Integrative Health and the Centers for Disease Control and Prevention's National Center for Health Statistics.
NIH/National Center for Complementary and Integrative Health, Centers for Disease Control and Prevention

Contact: NCCIH Press Office
nccihpress@mail.nih.gov
301-496-7790
NIH/National Center for Complementary and Integrative Health

Public Release: 11-Feb-2015
Nationwide survey reveals widespread use of mind and body practices
A large nationally representative survey shows that the number of Americans using mind and body approaches to improve health and well-being remains high. Of note is a significant increase in the use of yoga since 2002. In addition, almost as many Americans practice meditation or receive chiropractic or osteopathic manipulation. The complementary health questionnaire was developed by NIH's National Center for Complementary and Integrative Health and the Centers for Disease Control and Prevention's National Center for Health Statistics.
NIH/National Center for Complementary and Integrative Health, Centers for Disease Control and Prevention's National Center for Health Statistics

Contact: NCCIH Press Office
nccihpress@mail.nih.gov
301-496-7790
NIH/National Center for Complementary and Integrative Health

Public Release: 10-Feb-2015
JAMA
Study shows iron supplementation after blood donation shortens hemoglobin recovery time
A National Institutes of Health-funded study comparing low dose iron supplementation to no supplementation in blood donors found that supplementation significantly reduced the time to recovery of post-donation lost iron and hemoglobin -- an iron-rich protein that carries oxygen in red blood cells throughout the body.
NIH/National Heart, Lung, and Blood Institute

Contact: NHLBI Office of Communications
Nhlbi_news@nhlbi.nih.gov
NIH/National Heart, Lung and Blood Institute

Public Release: 9-Feb-2015
2015 Avant-Garde Awards offer extraordinary ideas in HIV/AIDS research
With proposals ranging from innovative therapies to the development of unique organoid models of the brain, five scientists have been selected to receive the 2015 Avant-Garde Award for HIV/AIDS Research from the National Institute on Drug Abuse, part of the National Institutes of Health. The five scientists will each receive $500,000 per year for five years to support their research.
NIH/National Institute on Drug Abuse

Contact: NIDA Press Office
media@nida.nih.gov
301-443-6245
NIH/National Institute on Drug Abuse

Public Release: 9-Feb-2015
NIH-funded research lays groundwork for next-generation prosthetics
Three groups of researchers who have received support from the National Institutes of Health will obtain funding from the President's BRAIN Initiative to improve artificial limb technology. The new awards will be funded and administered by the Defense Advanced Research Projects Agency and will build on the fundamental discoveries that were made possible by National Institute of Health support.
Defense Advanced Research Projects Agency

Contact: Barbara McMakin
nindspressteam@ninds.nih.gov
NIH/National Institute of Neurological Disorders and Stroke

Public Release: 5-Feb-2015
NIEHS funds 6 early-career researchers for innovative science
New grants totaling $3 million will go to six outstanding early-career scientists, bridging a funding gap to independent biomedical research. The National Institute of Environmental Health Sciences, part of the National Institutes of Health, created the award to encourage early stage researchers who want to discover how our environment influences human health.
NIH/National Institute of Environmental Health Sciences

Contact: Joe Balintfy
balintfyj@niehs.nih.gov
919-541-1993
NIH/National Institute of Environmental Health Sciences

Public Release: 5-Feb-2015
Cell
NIH researchers describe spontaneous cure of rare immune disease
A genetic phenomenon called chromothripsis, or 'chromosome shattering,' may have spontaneously cured the first person to be documented with WHIM syndrome, according to researchers at the National Institutes of Health. The patient was the subject of a 1964 study that first described the disorder, a syndrome of recurrent infections, warts and cancer caused by the inability of immune cells, particularly infection-fighting neutrophils, to leave the bone marrow and enter the bloodstream.
NIH/National Institute of Allergy and Infectious Diseases

Contact: Linda Huynh
niaidnews@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases

Public Release: 4-Feb-2015
New England Journal of Medicine
Paramedics may be first line of treatment for stroke
There is no time to waste when it comes to stroke. A study designed to test the benefits of early administration of magnesium sulfate suggests that stroke patients may not have to wait until they get to the hospital for treatment -- paramedics may be able to start therapy as soon as stroke is suspected. Although the drug did not improve outcome in stroke patients, the study demonstrated the feasibility of early therapy in the ambulance.
NIH/National Institute of Neurological Disorders and Stroke

Contact: Barbara McMakin
nindspressteam@ninds.nih.gov
NIH/National Institute of Neurological Disorders and Stroke

Showing releases 76-96 out of 96.

<< < 1 | 2 | 3 | 4

     
   

HOME    DISCLAIMER    PRIVACY POLICY    CONTACT US
Copyright ©2015 by AAAS, the science society.